ライフサイエンスコーパス: body weight gain

1 and banana as triggers were at risk of poor body weight gain.

2 icantly decreased food and water intake, and body weight gain.

3 w without alterations in rearing behavior or body weight gain.

4 ity, family history, food aversion, and poor body weight gain.

5 ciency, such as reduced food intake and poor body weight gain.

6 normoglycemic over 60 days, and had reduced body weight gain.

7 -161503 decreased food intake and attenuated body weight gain.

8 and lipids in animal models without causing body weight gain.

9 acid concentrations and reduces the rate of body weight gain.

10 factor-I, IGF binding protein-3, leptin, or body weight gain.

11 , less time attached to the nipple, and less body weight gain.

12 n any animal and did not suppress group mean body weight gain.

13 Neither genistein nor soy products reduced body weight gain.

14 EA used induced no toxicity or alteration in body weight gain.

15 oubled median life span, and extended normal body weight gain.

16 induced by high-fat diet feeding and reduces body weight gain.

17 tion, resulting in increased food intake and body weight gain.

18 the adaptation to oral feeding and optimized body weight gain.

19 ipulation can result in a robust and chronic body weight gain.

20 n and glucose concentrations associated with body weight gain.

21 mpanied by an increase in food intake and in body weight gain.

22 te physical activity, which in turn prevents body weight gain.

23 lso prevented the amylin-induced decrease of body weight gain.

24 -biased skin inflammation before significant body weight gain.

25 type VMH significantly increases feeding and body weight gain.

26 y lost, resulting in rapid WAT expansion and body weight gain.

27 ntagonist, significantly reduced the rate of body weight gain.

28 inhibited jejunal contraction, and decreased body-weight gain.

29 otype with reduced microglial activation and body-weight gain.

30 sufficient to protect mice from diet-induced body-weight gain.

31 ted commercial vaccines, with no decrease in body weight gains.

32 esent such an underweight state that resists body-weight gain?

33 hat did not adjust for energy showed greater body weight gain (0.21 kg; 95% CI, 0.15-0.27 kg) than st

34 ient to decrease pup mortalilty, to increase body weight gain (+0.1 g/day) and to delay the onset of

35 del of high-fat diet-induced obesity reduced body weight gain, adiposity and insulin resistance.

36 ned by adrenal gland weight, and verified by body weight gain after repeated restraint stress, and fe

37 normalize energy intake and showed increased body weight gain after the HFD challenge.

38 ws prediction of ROP risk based on postnatal body weight gain alone.

39 R2 blockade in ob/ob mice leads to a reduced body-weight gain, an improvement in insulin sensitivity,

40 n zebrafish in vivo accelerates diet-induced body weight gain and adipocyte enlargement.

41 Body weight gain and adipose tissue mass were significan

42 Food intake, body weight gain and adiposity were greater for rats tha

43 Resveratrol therapy significantly reduced body weight gain and adiposity, lowered plasma and hepat

44 of male breeders reduced their week-on-week body weight gain and altered NR3C1 and CRH gene expressi

45 The 129P1 donor allele conferred lower body weight gain and better glucose handling during intr

46 neal administration of LEP-(116-130) reduced body weight gain and blood glucose levels but not food i

47 t diet for 10 weeks, CCK-KO mice had reduced body weight gain and body fat mass and enlarged adipocyt

48 Surviving animals resumed normal body weight gain and clinical performance within 5 days

49 ch mediates an indirect relationship between body weight gain and corpus callosum growth.

50 an improved metabolic phenotype with reduced body weight gain and enhanced glucose tolerance by induc

51 omosome 7, which had a synergistic effect on body weight gain and fat deposit with the znt7-null muta

52 rhythms in temperature, locomotor activity, body weight gain and food intake and adipose depot weigh

53 Subsequently, body weight gain and food intake increased and caloric e

54 in-expressing astrocytes induced exaggerated body weight gain and glucose intolerance in mice exposed

55 o overexpression of G3PP in rat liver lowers body weight gain and hepatic glucose production from gly

56 -PL supplementation to obese dams suppressed body weight gain and hyperinsulinemia in both dams and o

57 al white adipose tissue, with an increase in body weight gain and impaired insulin signaling.

58 vo acrylamide injection transiently impaired body weight gain and impaired one-trial inhibitory avoid

59 tected diet-induced obese (DIO) mice against body weight gain and improved multiple metabolic paramet

60 neurons is necessary for protection against body weight gain and induction of UCP1 in adipose tissue

61 inoid-1 receptor (CB(1) R) blockade reverses body weight gain and insulin resistance and increases en

62 eveal that microglial EP4 signaling promotes body weight gain and insulin resistance during HFD feedi

63 e, high-fat diet (HFD) causes more prominent body weight gain and insulin resistance than in wild-typ

64 VSL#3 suppressed body weight gain and insulin resistance via modulation o

65 (-/-)) mice were protected from HFD-enhanced body weight gain and insulin resistance.

66 n was assessed 6 days after challenge, using body weight gain and intestinal lesion scores.

67 their pharmacological stabilization, reduces body weight gain and levels of inflammatory cytokines, c

68 ct of LA was associated with almost 40% less body weight gain and lower serum and very low-density li

69 t mass increase, contributing to accelerated body weight gain and metabolic disorders.

70 ese angiogenesis-targeted NPs have inhibited body weight gain and modulated several serological marke

71 ised C57BL/6J-mouse dams were protected from body weight gain and NAFLD in adulthood (postnatal day (

72 atory ratio controlled inflammation, reduced body weight gain and protected from hyperglycemia on hig

73 DNT5 caused highly significant reduction in body weight gain and reduced adipocyte size after 6 and

74 BP increased the body weight gain and reduced the feed conversion ratio (

75 howed no significant changes in food intake, body weight gain and relative weight of vital organs.

76 d progression of motor dysfunction, improved body weight gain and survival with the amelioration of n

77 esistance or high insulin secretion promotes body weight gain and the development of insulin resistan

78 to attenuate the L-CPA-induced reductions in body weight gain and the prevention of the loss in hindl

79 Subchronic treatment with OEA reduced body weight gain and triacylglycerol content in liver an

80 ion of resveratrol (10 ppm) had no effect on body weight gain and tumor volume but produced striking

81 MFGM-PL treatment to HFD dams decreased the body weight gain and WAT mass as well as lowered the ser

82 n rats, 5 days of amylin treatment decreased body weight gain and/or food intake and increased IL-6 m

83 te concentration and alleviated diet-induced body-weight gain and adiposity in mice.

84 ar dose, as seen by longer survival, greater body-weight gain and better preservation of motor neuron

85 The high-fat diet increased body-weight gain and plasma leptin levels.

86 ranosyl cytidine (AraC) blunted food intake, body weight gain, and adiposity.

87 on of Rb1 significantly reduced food intake, body weight gain, and body fat content and increased ene

88 We detected improved sleep, prevention of body weight gain, and deceleration of cardiac aging unde

89 iduals at risk for chronic hyperinsulinemia, body weight gain, and glucose intolerance.

90 onsequently, also improve dry matter intake, body weight gain, and in vitro embryo production when co

91 (MBH) reduces food intake, protects against body weight gain, and limits adiposity, suggesting that

92 issue microenvironment (ATME) evolves during body-weight gain, and how these changes might influence

93 hyperphagia of these mice led to accelerated body weight gain as compared with otherwise matched cont

94 was paralleled by decreased food intake and body weight gain as well as increased energy expenditure

95 CSEE caused dose-related reductions in body weight gain (as well as plasma lipid levels and epi

96 rains in the gut (~5 logs) and increased the body-weight-gain at 4-5 weeks of age compared to non-RB

97 ced the formation of hepatic lipid droplets, body weight gain, blood glucose, and improved serum bioc

98 ic-exposed females had significantly greater body weight gain, body fat content, and glucose intolera

99 This treatment attenuated HFD-induced body weight gain, body fat mass accumulation, increased

100 ss sensitive than APOE3 mice to diet-induced body weight gain but exhibited hyperinsulinemia, and the

101 oleoylethanolamide (OEA) reduces feeding and body weight gain by activating the nuclear receptor PPAR

102 HFD induced increased body weight gain, circulating levels of leptin, choleste

103 stent spatial memory deficits, and decreased body weight gain compared to experimental counterparts a

104 The NSD groups showed the highest (P < 0.05) body weight gain compared to HSD groups.

105 rotected birds against mortality but reduced body weight gain compared to the 7-day group vaccinated

106 treatment, PLAAT1 deficiency caused a lower body weight gain compared to wild-type mice.

107 ficient mice were protected from TZD-induced body weight gain compared with PPARgamma2-deficient mice

108 10 muL of daily oral CAGE exhibited 12% less body weight gain compared with rats fed with an HFD with

109 se early body weight gain while holding late body weight gain constant; E-LO was selected to decrease

110 C57BL/6 pups exhibited prolonged deficits in body weight gain (days 12-30) compared with BALB/c pups

111 interesting therapeutic approach to prevent body weight gain, decrease fat mass, and improve insulin

112 ion results in modulation of food intake and body weight gain, demonstrating significant therapeutic

113 Body weight gain did not differ between wild-type (WT) a

114 bH null mice displayed significantly reduced body-weight gain, diminished abdominal fat, and increase

115 consumption was not associated with greater body weight gain during 8 y of follow-up in healthy midd

116 Maternal body weight gain during gestation averaged 282 and 57 g

117 lts confirm the location for body weight and body weight gain during growth that were identified in p

118 ure had no effect on survival but did affect body weight gain during treatment.

119 16 globally have low birth weight, increased body weight gain, energy expenditure and hyperphagia.

120 consequences of hypercaloric diet, including body weight gain, energy expenditure, and fatty acid oxi

121 , there were no changes in mean body weight, body weight gain, food consumption or food efficiency fo

122 h- and low-calorie chips exhibited increased body weight gain, food intake and adiposity when they we

123 hese effects were associated with attenuated body weight gain, food intake and improved physiological

124 and brain energy use is inversely related to body weight gain from infancy until puberty.

125 Repetitive TBI did not affect body weight gain, general neurological deficit severity,

126 f central PPARgamma promotes food intake and body weight gain; however, the identity of the neurons t

127 broad metabolic dysfunction characterized by body weight gain, hyperinsulinemia, dyslipidemia and imp

128 The results revealed that daily body weight gain improved (P < 0.05) by 18.64% and 23.94

129 TRF prevents excessive body weight gain, improves sleep, and attenuates age- an

130 NGF suppressed the body weight gain in 4MO rats but did not affect 23MO rat

131 5-HT2C antagonist and caused a reduction in body weight gain in a 4-day rat model.

132 component of energy homeostasis that alters body weight gain in a gender-specific fashion.

133 tration of 33A did not affect food intake or body weight gain in a mouse model of diet-induced obesit

134 atment groups; however, naltrexone decreased body weight gain in both lactating and post-lactating su

135 increased cumulative food intake and overall body weight gain in controls but they increased subcutan

136 tors block host protein digestion and reduce body weight gain in diet-induced obese rats and mice, an

137 L-NAME significantly reduced body weight gain in DIO but not in chow-fed rats.

138 g the persistent low birth weight, increased body weight gain in early adulthood, increased energy ex

139 is associated with increased food intake and body weight gain in female rats; to evaluate whether thi

140 The decreased body weight gain in GPRKO female mice is due to the redu

141 lucose tolerance and reduces food intake and body weight gain in healthy, obese and diabetic rats.

142 essing cells markedly decreases fat mass and body weight gain in mice and induces the expression of t

143 f body weight, we found that the decrease in body weight gain in mice treated with metformin is not d

144 sociated with a reduction of food intake and body weight gain in normal and obese animals.

145 During lactation, maternal HFD increased body weight gain in offspring.

146 Food intake and body weight gain in other rats with partial lesions of t

147 ogical levels of insulin are associated with body weight gain in patients.

148 The decrease body weight gain in PTL(-/-) and PTL(-/-), CEL(-/-) mice

149 se-dependently suppress food consumption and body weight gain in rats following single intraperitonea

150 RNA resulted in hyperphagia and exacerbated body weight gain in rats maintained on high-fat diet.

151 th high GC concentrations, usually decreases body weight gain in rats; by contrast, in stressed or de

152 ses feed efficiency, relative adiposity, and body weight gain in relation to the immune response elic

153 ypothalamus, potently stimulates feeding and body weight gain in rodents.

154 hat Prlh expression in these cells restrains body weight gain in the face of high fat diet challenge

155 h control IgG but also significantly reduced body weight gain in the pups, suggesting an adverse effe

156 or fluid intake, physical activity levels or body weight gain in the rat, whereas it depleted muscle

157 ay dose, there was a significant decrease in body weight gain in the rats.

158 in the absence of any significant effect on body weight gain in the treated rats.

159 stration of OEA produces satiety and reduces body weight gain in wild-type mice, but not in mice defi

160 altered food intake, energy expenditure, and body weight gain in WT mice, FGF21-deficient animals did

161 de hormone PYY3-36 decreases food intake and body-weight gain in rodents, a discovery that has been h

162 4 microinjection to suppress food intake and body weight gain; in contrast, intracore NMDA receptor b

163 Triglycerides and body weight gain increased at all time points in the HF

164 The risk of poor body weight gain increased in FPIES triggered by cow's m

165 ss of CTR in POMC neurons leads to increased body weight gain, increased adiposity, and glucose intol

166 iency of IRAKM reduces high-fat diet-induced body weight gain, increases whole body energy expenditur

167 Alcohol intake prevented body weight gain, induced the formation of uncoupling pr

168 CBC reduced body weight gain, inflammation, hepatic steatosis, hyper

169 Further, long-term dark rearing leads to body weight gain, insulin resistance, and glucose intole

170 rotein content 23.9%) increased food intake, body weight gain, lean body mass, and gastrocnemius musc

171 t 0.2 and 0.3 mg/kg enhanced body weight and body weight gain linearly compared to the control diet a

172 treadmill exercise during pregnancy reduced body weight gain, lowered serum glucose and lipid concen

173 In ob/ob mice, EAT gene transfer suppresses body weight gain, maintains metabolic homeostasis, and c

174 After birth they are characterized by low body weight gain, marked hypotension, and abnormal kidne

175 addition of SSBs to the diet led to greater body weight gain (MD: 0.83 kg; 95% CI: 0.47 kg, 1.19 kg)

176 Body weight gain mean (SD) was similar in PUFA (2.01 +/-

177 CD40 deficiency (CD40KO) resulted in greater body weight gain, more severe inflammation in epididymal

178 AAV9.BVES dramatically improved body weight gain, muscle mass, muscle strength, and exer

179 -I or both resulted in significantly greater body weight gain, nitrogen retention, and serum total IG

180 On average, the body weight gain of 3NOP-treated cows was 80% greater th

181 The mean percentage body weight gain of GH transgenic channel catfish was 55

182 Furthermore, the reduced body weight gain of the mutant mice was largely due to t

183 emonstrate that TPL2 deletion does not alter body weight gain or adipose depot weight.

184 Despite of showing no changes in body weight gain or adiposity, mice on WD-CO exhibited s

185 ces either increased comfort food intake and body weight gain or decreased intake and body weight los

186 t murine models, independently of changes in body weight gain or plasma lipid profile.

187 pletion, there was no effect on food intake, body weight gain, or total carcass adiposity on chow or

188 mice fed a chow diet presented with blunted body-weight gain over time, had lower fat mass, and were

189 E4, animals with dietary n-3 PUFAs decreased body-weight gain, plasma lipids, and insulin (P < 0.05)

190 -bearing rats were accompanied by attenuated body weight gain post-LPS.

191 y 9 was found to be effective in suppressing body weight gain relative to control in a diet-induced o

192 associated with a significant retardation of body weight gain shortly after sulfone administration an

193 induced diabetes results in normalization of body weight gain, significant control of hyperglycemia a

194 d without overt clinical disease, but showed body weight gains significantly reduced by 6.5-11.4% beg

195 in high-fat diet rats led to a reduction in body weight gain similar to dapagliflozin with superior

196 These alterations occur without prominent body weight gain, suggesting that a high-fat diet acts i

197 d to OSPM exhibited significant decreases in body weight gain, systemic oxidative stress in the form

198 t diet, the IAP-deficient mice showed faster body weight gain than did control animals.

199 gnificantly lower oocyst shedding and normal body weight gain than nonvaccinated and infected control

200 eatment groups consistently displayed higher body weight gain than the untreated chicks.

201 the MeA of adult male mice produced a rapid body weight gain that was associated with remarkable red

202 etabolic changes were sufficient to increase body weight gain under normal chow feeding and exacerbat

203 tained reduction in blood glucose levels and body weight gains up to 5-7 days, whereas the efficacy o

204 However, body weight gain was 6.2 and 8.6 g less (p < 0.01) in PT

205 Body weight gain was accelerated in rAAV-GFP + HFD contr

206 ese findings and demonstrated that increased body weight gain was also demonstrated when animals cons

207 condition factor, specific growth rates, and body weight gain was also found to be promising compared

208 Body weight gain was not significantly different among g

209 A reduction in body weight gain was observed in ApoE(-/-) mice fed a hi

210 Increases in body mass index and percentage body weight gain were also significantly lower in women

211 ays posthatch, and fecal-oocyst shedding and body weight gain were determined as parameters of coccid

212 Daily food consumption and body weight gain were not affected.

213 Mean body weight gains were not significantly different betwe

214 k physiological mechanisms to defend against body weight gain when food is abundant.

215 minal fat independent of caloric content and body weight gain, whereas increasing meal size did not.

216 follows; E+LO was selected to increase early body weight gain while holding late body weight gain con

217 f diet-dependent microglia expansion hinders body weight gain while preventing central and peripheral

218 misalignment of circadian rhythms promoting body weight gain, while consumption of a calorie-dense d

219 enesis, and P2Y(2)R knockout decreased mouse body weight gain with smaller eWAT mass infiltrated with

220 administration of 11 reduced food intake and body weight gain without causing CNS-related malaise.

221 gh-producing dairy cows by 30% and increased body weight gain without negatively affecting feed intak

222 3aR1-MphiKO and C3aR1-KpKO mice have similar body weight gain without significant alterations in gluc

223 Minimal intermittent stimulation led to body weight gain; ZI GABA neuron ablation reduced weight